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Keratins, formerly known as cytokeratins, are the major epithelial-specific subgroup of intermediate filament proteins. Adult
hepatocytes express keratin polypeptides 8 and 18 (K8/K18), whereas cholangiocytes express K8/K18 and keratins 7 and 19 (K7/
K19). Keratins function primarily to protect hepatocytes from apoptosis and necrosis, which was revealed using several genetic
mouse models. This cytoprotective function was further clarified by the identification of natural human keratin variants that are
normally silent, but become pathogenic by predisposing their carriers to apoptosis during acute or chronic liver injury mediated
by toxins, virus infection, or metabolic stress. During apoptosis, caspases cleave K18 and K19 at conserved aspartates (human
K18/K19: 235Val-Glu-Val-Asp#) and K18 at a unique aspartate (human K18: 394Asp-Ala-Leu-Asp#), with the latter exposed
epitope becoming recognized by the M30 antibody in blood and tissues. Additional K18-containing protein backbone epitopes
are detected using the M6 and M5 (termed M65) antibodies. Intact K18 and its associated fragments, which are released into
blood during apoptosis and necrosis in various diseases, have been analyzed by enzyme-linked immunosorbent assay using the
M30/M65 antibodies or their signal ratios. Furthermore, M30/M65 levels have been used as diagnostic and prognostic bio-
markers in acute and chronic liver diseases, including nonalcoholic steatohepatitis and acute liver failure. Other keratin bio-
markers include K8/K18/K19-related tissue polypeptide antigen, K18-related tissue polypeptide-specific antigen, and K19-
related CYFRA-21-1, which have been evaluated mostly in patients with epithelial tumors. Conclusion: Keratins and their frag-
ments are released into blood during liver and other epithelial tissue injury. The epithelial specificity of K18/K19, epitope
unmasking upon caspase digestion, keratin abundance, and relative keratin stability render them useful biomarkers for hepato-
cyte and cholangiocyte apoptosis and necrosis. However, the precise biochemical nature and release mechanism of circulating
keratins remain unknown. (HEPATOLOGY 2016;64:966-976)
T
he cytoskeleton of most mammalian cells
includes three major filament networks: micro-
filaments, microtubules, and intermediate fila-
ments (IFs).(1) IFs consist of a large family of tissue-
specific proteins that include the cytoplasmic keratins as
the largest subgroup, vimentin, neurofilaments, and
lamins, among others.(2-4) Keratin (K) IFs are selectively
expressed in epithelial cells and serve as cell-specific
markers.(5) Whereas early publications referred to kera-
tins as cytokeratins,(6) and the latter term remains used
by some, keratins is now the recommended name based
on an internationally accepted consensus(7) and this is
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the term we use and recommend. All IFs share a com-
mon protein organization backbone that consists of a
central a-helical “rod” domain that is flanked with non-
a-helical “head” and “tail” domains.(8) Keratins consist
of type I (K9-K28, K31-K40) and II (K1-K8, K71-
K86) IFs(2,7) that form obligate noncovalent heteropoly-
meric type I/II complexes that polymerize to form char-
acteristic 10-nm-wide filamentous arrays. A unique
feature of the different type I/II keratin pairs is their epi-
thelial cell-specific expression. For example, K5/K14
and K1/K10 are found in basal and suprabasal keratino-
cytes, respectively, whereas combinations of the type II
K7 or K8 and type I K18/K19/K20/K23 are expressed
in simple-type (single-layered) epithelial cells as found
in digestive-organ epithelia.(9) K8 and K18 are the only
keratins found in adult hepatocytes, whereas cholangio-
cytes express K7/K19 with K8/K18.(9)
Apoptosis and necrosis are the typical modes of cell
death in liver diseases, including viral, fatty, cholestatic,
and alcohol-related disorders.(10) The apoptotic pathway
is triggered by binding of extracellular death ligands,
such as Fas ligand or tumor necrosis factor alpha (TNF-
a), to death receptors (Fas and TNF-R1/R2 receptors,
respectively) and is culminated by caspase activation and
degradation of numerous cellular proteins.(11,12) Indeed,
mice treated with a Fas agonist antibody develop acute
liver failure and may die depending on the experimental
conditions.(13) Among the many substrates that are
cleaved during apoptosis are the cytoskeletal compo-
nents actin,(14) tubulin,(15,16) and several IFs, including
lamins(17) and keratins.(18,19) Notably, only type I, but
not type II, keratins are caspase substrates.(19)
Keratins in the liver serve several important
mechanical and nonmechanical cellular and subcellu-
lar functions. The K8/K18 mechanical function,(20,21)
similar to other IFs,(5) endows hepatocytes with sta-
bility that protects them from necrosis.(9) This
mechanical function, which allows cells and tissues to
cope with deformations, sets IFs apart from microfila-
ments and microtubules.(22) Nonmechanical func-
tions of keratins include facilitation of protein
targeting to subcellular compartments,(9) modulation
of protein synthesis,(23) organelle positioning,(24) and
protection from apoptosis and necrosis.(23-25) This
review focuses on hepatobiliary aspects related to: (1)
biochemical events that lead to keratin proteolysis by
caspases during apoptosis; (2) keratin functions
related to cell injury and death; and (3) the utility and
caveats of measuring keratin fragments as biomarkers
of liver injury.




Keratins undergo several covalent post-translational
modifications (PTMs), including phosphorylation,
glycosylation, ubiquitination, sumoylation, transamida-
tion, and acetylation.(26) These modifications regulate
keratin filament organization, subcellular localization,
solubility, turnover, interaction with binding proteins,
and, consequently, keratin function. The best under-
stood modification is keratin phosphorylation, which is
highly relevant because significant increases in keratin
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phosphorylation occur in the context of cell injury
attributed to activation of stress and other
kinases.(26,27) Keratin phosphorylation is among the
earliest biochemical events that take place after an apo-
ptotic stimulus, and mice that express phospho-mutant
human K18 Ser53Ala(28) or K8 Ser74Ala(29) are pre-
disposed to Fas-mediated liver injury.
Another form of a noncovalent keratin PTM is pro-
teolysis of type I keratins, including K18 and K19, by
caspases during apoptosis.(9) K18 has two caspase rec-
ognition sites (Fig. 1): VEVD238, which is conserved
across species and most IFs, and a unique DALD397
site that is present only in K18 and not other keratins/
IFs(18,19,30) (Table 1). The caspase-mediated K18
cleavage occurs first at the aspartate of DALD397# and
then at VEVD238#,(30,31) with the first cleavage event
occuring early before detection of Annexin V staining
and DNA fragmentation.(30,32) Notably, the unmasked
neoepitopes at K18 VEVD238 or DALD397 are
detected by epitope-specific antibodies: a mouse
monoclonal M30 antibody recognizes the fragment
ending with DALD397, whereas a rabbit polyclonal
antibody recognizes the fragment ending with
VEVD238.(33,34) Such antibodies provide powerful
tools to assess epithelial cell apoptosis by detecting and
quantifying apoptotic and nonapoptotic K18 (and
K19) species in serum/plasma. The M30 and M65
enzyme-linked immunosorbent assays (ELISAs) have
been used in more than 100 liver- and non-liver-
related studies to assess disease activity and the contri-
bution of apoptosis or total cell death to disease patho-
genesis (Supporting Table S1).
Caspase-mediated cleavage of cytoskeletal compo-
nents, including K18/K19, is presumed to allow reor-
ganization of the filament network, thereby permitting
retraction of the affected cells and membrane blebbing
that are observed at early stages of apoptosis.(11)
Although it is known that the three major cytoskeletal
elements are caspase substrates,(14,15) including cyto-
linker proteins such as plectin,(35) the orchestration
and sequence of cytoskeleton alterations are poorly
understood.
The physiological significance of caspase-mediated
K18 cleavage appears to be related to allowing keratin
filaments to reorganize. This is supported by findings
in transgenic mice that overexpress a caspase-resistant
K18 mutant (K18-DE) with Asp (D)-to-Glu (E)
mutation at the two caspase cut sites (D238/D397).
Keratin filaments in livers and isolated hepatocytes
from K18-DE mice were not able to reorganize and
disassemble upon Fas stimulation in vivo and ex
vivo.(34) These mice also developed more severe Fas-
triggered liver damage, as compared to mice that over-
expressed wild-type (WT) K18. The enhanced K18
DE liver injury is attributed to shunting of cell death
from apoptosis to necrosis in association with keratin
hypophosphorylation(34) at a serine that normally pro-
tects from apoptosis when phosphorylated.(29) Hence,
K18 caspase cleavage during apoptosis allows for the
progression of keratin reorganization during apoptosis
(Fig. 2). The mechanism of the shunting of cell death
TABLE 1. Conserved Caspase Recognition
Sites Across Species
Species K18 VEVD K18 DALD K19 VEVD
Human SGLTVEVDAPK NLGDALDSSN GGQVSVEVDSAPG
Cow SGLTVELDAPK SLGDALDSSN GGQVSVEVDSAPG
Mouse SGLTVEVDAPK SLNDALDSSN GGQVSVEVDSTPG
Opossum SGLTVEVDSPK NLVHALDGSS GGQVSVEVDSAPG
Chicken SGLTVEVDSPK NLVHALDGSS ASQVSVEVDSAPG
Frog NNVKVEVEGPK NLMDLNQQIS GGQISVEVDAAPT
Zebrafish SQSGVQVDVDA KLQDALEEQG Unknown
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FIG. 1. K18 cleavage during apoptosis. Human K18 has two
caspase cleavage sites. VEVD238 is highly conserved among other
IFs, whereas the DALD397 is unique to K18. The cleavage
occurs sequentially at DALD397 and then VEVD238. The D238
antibody specifically recognizes the neo-epitope VEVD238,
whereas the M30 antibody recognizes DALD397 digestion.(30,33)
M65 are two monoclonal antibodies, M6 and M5, that recognize
K18 epitopes between amino acids 300-380(88) (PEVIVA AB,
Bromma, Sweden). TPS antibody recognizes a K18 epitope
within amino acids 322-340.(87,88) The caspase-cleaved K18 frag-
ments are finally further degraded by presumed proteinases (?).
Abbreviations: Ab, antibody; aa, amino acid.
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toward necrosis when K18 cleavage is blocked remains
to be investigated.
Keratin Variants Predispose
to Cell Death and Liver
Disease Progression
The essential cytoprotective function of keratins is
supported by more than 60 different disorders that are
linked to the presence of inherited keratin variants
(www.interfil.org).(36-38) For example, KRT8 and
KRT18 variants associate with progression of several
chronic liver diseases, including hepatitis C, primary
biliary cirrhosis (PBC), and what was initially associ-
ated with cryptogenic cirrhosis that is likely primarily
attributed to nonalcoholic fatty liver disease
(NAFLD).(39,40) In addition, K19 G17S substitution
associates with disease progression in patients with
PBC.(41) Further studies are needed to evaluate the
biological importance of this and other potential K19
variants. K8/K18 variants also associate significantly
with acute liver failure (ALF) progression and the need
for liver transplantation (LT) or patient death.(42) In
addition, K18 (D90H) and K8 (K393R) mutation at
residues that disrupt keratin cytoskeletal organization
were found in 2 patients who died from isoniazid and
ezetimibe/simvastatin hepatoxicity, respectively.(38)
The mechanism by which human keratin variants
predispose to liver injury appears to be primarily non-
mechanical. For example, some variants impair keratin
phosphorylation at adjacent residues, which renders
K18 more susceptible to digestion by caspases. The
mutation-triggered predisposition to apoptosis is path-
way dependent, in that two different K18 mutations in
transgenic mice predispose to Fas, but not TNF-
mediated apoptosis.(34,43) As compared with epidermal
keratin mutations, which as a group cause disease and
are highly penetrant, K8/K18 variants predispose to
(liver) disease rather than cause disease per se, are more
common and display race/ethnic associations.(9,38,42)
For example, K8 Y54H and G434S are the most com-
mon amino-acid-altering variants in individuals of
African descent and are found in 3.6% and 8% of
liver-healthy groups, respectively.(38,44) In contrast, K8
G62C and R341H are the most abundant substitu-
tions found in Caucasians (variant frequencies 1%-2%
and 6%, respectively).(38) The K8/K18 common var-
iants are typically located in less-conserved keratin
regions (head and tail, Fig. 1), whereas mutations in
the most-conserved K8/K18 subdomains are rare
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FIG. 2. Effect of inhibiting K18 fragmentation on keratin filament organization and Fas-mediated liver damage. Mutation of the
two K18 caspase cleavage sites (K18 DE) results in several consequences, including keratin hypophosphorylation, inability of the kera-
tin filaments to reorganize, and shunting toward cell necrosis rather than apoptosis. Abbreviations: Ab, antibody; MAPK, mitogen-
activated protein kinase.
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(variant frequencies <0.1%).(38) An extensive body of
works indicate that keratin variants predispose their
carriers to both apoptotic and nonapoptotic cell death
depending on the pathological challenge and location
of the mutation.(9,23,25,29,34,38)
Clinical Utility of K18 as a
Liver Disease Biomarker
Liver biopsy represents the gold standard for diag-
nosis and evaluation of the activity or progression of
liver diseases, but it bears important risks. Given that a
liver biopsy specimen represents 1 in 50,000 of the
total liver mass, sampling errors might limit interpreta-
tions.(45) Intra-/interobserver variability may also con-
tribute to misinterpretations.(46) Therefore, much
attention has focused on the identification of noninva-
sive biomarkers that can detect liver disease activity or
progression. Increased apoptosis and/or necrosis play a
role in the pathogenesis of various liver diseases and
determine disease activity and progression.(10,47,48)
Thus, biomarkers of hepatocyte apoptosis or necrosis
have been used to monitor acute and chronic liver dis-
eases. During hepatocyte apoptosis, activated caspases
cleave K18, which can be detected in serum or plasma
by the M30 ELISA,(49) whereas the M65 ELISA
detects both caspase-cleaved and uncleaved (total)
K18.(49,50) Several mechanisms may contribute to K18
release to the extracellular space. As such, K18 frag-
ments form cytoplasmic inclusion bodies and occur in
apoptotic cell-surface blebs,(51) and keratins can circu-
late in serum within extracellular vesicles.(52) Further
studies are needed to delineate the modes of keratin
release from cells (e.g., within vesicles, apoptotic
bodies, full length, apoptotic and nonapoptotic frag-
ments). Findings from these studies will likely refine
the currently used assays and enhance their utility.
Here, we summarize studies that have utilized kera-
tins as potential biomarkers in acute and chronic liver
disease. We focus on primary hepatobiliary diseases,
although the M30/M65 ELISAs have been used in
other glandular-tissue-type injury, such as gastrointes-
tinal/liver graft-versus-host disease (GVHD).(53)
Role of K18 Biomarkers in
Acute Liver Diseases
ALF is potentially life threatening, whereby the
decision for LT should be made as early as possible.
Therefore, noninvasive biomarkers are urgently
needed. Notably, ALF patients have significantly
higher circulating levels of caspase-cleaved (M30) and
presumed total K18 (M65), as compared to healthy
individuals.(50,54,55) Whether apoptotic and/or necrotic
cell death predominates in ALF and how their propor-
tion influence the outcome remain largely unclear and
likely depend on the etiology, severity, and duration of
the ALF.(56) Nevertheless, it was demonstrated that
modification of the Model for End-Stage Liver Dis-
ease (MELD) score by substitution of bilirubin with
total K18 significantly improved the prediction of
ALF outcome at the day of hospital admission.(57)
Moreover, the U.S. ALF Study Group proposed an
ALF index that combines clinical markers and M30
levels and thus allowed better prediction of ALF out-
come as compared to the routinely used King’s College
Criteria (KCC) or MELD score.(58) However,
although serological detection of M65 or M30 levels
allowed the prediction of ALF outcome in paracetamol
intoxication,(59,60) neither M30 nor M65 levels were
superior to KCC in those patients.(61) Thus, combina-
tion of these cell death biomarkers with other prognos-
tic parameters of ALF might be required to improve
the assessment of ALF outcome.
Role of K18 Biomarkers in
Chronic Liver Diseases
VIRAL HEPATITIS
Chronic hepatitis B or C virus (HBV/HCV) infec-
tions are accompanied by variable degrees of hepatic
inflammation and fibrosis. Apoptosis plays an impor-
tant role in inflammatory liver damage and fibrosis
progression and is associated with increased risk of cir-
rhosis and hepatocellular carcinoma (HCC).(62) For
example, caspase-mediated K18 cleavage correlated
with inflammatory disease activity in livers from
patients with chronic HCV infection.(49) Similarly,
patients with chronic HBV infection showed higher
serum M30 levels compared to healthy controls.(63)
M30 serum levels correlated with histological disease
activity in chronic HCV or HBV infection.(64,65) Vice
versa, M30 levels declined with successful antiviral
treatment of chronic HCV or HBV infection.(66,67)
Elevated M30 levels could even be detected in sera
from patients with chronic HCV or HBV infection
and normal aminotransferase activity.(49,63,68) In this
respect, patients with HBeAg-negative chronic HBV
infection and transiently normal aminotransferases had
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higher M30 serum levels compared to inactive car-
riers.(63) Interestingly, the majority of patients with
chronic HCV infection and normal aminotransferase
levels had histological evidence of progressive fibro-
sis,(49) which is consistent with other studies showing
elevated M30 levels in association with advanced fibro-
sis or cirrhosis (Supporting Table 1).(68,69) Both apo-
ptosis and necrosis have been proposed as responsible
for development and progression of liver fibrosis.(62)
However, unlike the M30 ELISA, detection of total
K18 by the M65 ELISA might allow the discrimina-
tion of lower fibrosis stages in chronic liver disease.(69)
Whether differential sensitivity in detection of lower
fibrosis stages between the M30 and M65 assays
reflects different cell death modes or whether different
stability of the K18 forms might influence the sensitiv-
ity remains to be investigated.
NAFLD
NAFLD is one of the most common causes of
chronic liver diseases, ranging from simple steatosis to
nonalcoholic steatohepatitis (NASH) with the risk of
developing liver cirrhosis and HCC.(70) Notably, ami-
notransferase levels are within the normal range in
nearly 80% of patients with fatty liver.(71) However,
NASH can be diagnosed in up to 59% of patients
despite normal aminotransferases,(72,73) and >50% of
patients with steatosis progress toward NASH and
more than half of them develop fibrosis progression
within 3 years.(74) Therefore, novel biomarkers to
detect NAFLD activity and monitor disease progres-
sion are needed. Because hepatocyte apoptosis plays a
critical role in NAFLD-associated liver injury, and
aminotransferases are not sensitive enough for the diag-
nosis of NASH, the M30 assay became an extensively
evaluated marker for detecting NAFLD activity.(75)
Early studies showed that plasma M30 is higher in
patients with NASH, compared to steatosis, and might
allow discrimination between both entities.(76) Subse-
quent studies (Supporting Table 1) confirmed an
increase of caspase-cleaved K18 fragments in NASH
patients compared to patients with simple steatosis.(69)
The diagnostic performance of K18 fragments in
NASH detection was promising, with area under the
curve (AUC) values ranging from 0.77 to 0.93.(77)
However, the diagnostic performance of caspase-
cleaved K18 for detection of NASH has been recently
questioned,(78) given that AUC values of 0.65 and of
0.68 were calculated for prediction of NASH or fibro-
sis, respectively, in NAFLD patients.(78) Nevertheless,
plasma/serum K18 fragment levels were significantly
higher in NAFLD patients with moderate-to-severe
fibrosis compared to those with no or mild fibro-
sis.(77,79) Moreover, K18 fragments correlated signifi-
cantly with the degree of steatosis, lobular
inflammation, and ballooning(77,79-81) and more accu-
rately reflected histological NAFLD Activity Score
(NAS)(82) compared to alanine aminotransferase
(ALT) levels.(81) In addition, changes in M30 levels
closely paralleled NAS,(75,81) which was not observed
for aminotransferase levels.(81) Another study con-
firmed a significantly stronger decrease of M30 levels
in patients with histological improvement compared to
those without changes in NAS, although reductions in
M30 levels were not better than ALT levels for identi-
fication of patients with histological NAFLD improve-
ment.(83) Similarly, M30 levels declined significantly in
parallel with aminotransferase levels in NAFLD
patients after bariatric surgery.(77)
In contrast to M65, M30 was unable to predict
NASH independently of ALT levels.(69) In line with
this observation, a composite model including both
ALT and caspase-cleaved K18 revealed a higher accu-
racy for prediction of NAFLD activity compared to
detection of caspase-cleaved K18 alone.(84) Otherwise, a
higher diagnostic performance of total K18, compared
to caspase-cleaved K18 for prediction of NASH, could
be demonstrated.(85,86) Further studies are needed to
explore whether total K18 levels might be superior for
predicting and monitoring of NAFLD disease activity.
In summary, the M30 and M65 ELISAs represent a
reliable and sensitive method for noninvasive detection
of liver disease activity and progression and have been
extensively evaluated in NAFLD (Fig. 3). Furthermore,
assessment of K18 fragments became part of prospective
NAFLD studies(74,87) and such data will help our
understanding of the usefulness of K18-based bio-
markers in this context.
KERATIN FRAGMENTS IN LIVER
CANCER AND NONMALIGNANT
LIVER DISEASES
Although M30/M65 currently represent the most
widely used keratin-based serum markers, other tumor
markers also rely on detection of keratin fragments.
For example, tissue polypeptide antigen (TPA) recog-
nizes K8, K18, and K19, whereas tissue polypeptide-
specific antigen (TPS) and keratin fragments 21-1
(CYFRA 21-1) detect K18 and K19, respectively.(9,40)
Several commercial assays exist for these markers(88)
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(Fig. 4). The epitopes recognized by M65 and TPS are
localized in the C-terminal portion of the rod domain,
with TPS being restricted to K18 amino acids 322-
340(89,90) (Fig. 1). Although the diagnostic benefit of
TPS, TPA, and CYFRA 21-1 have been evaluated in
multiple human malignancies and showed prognostic
value particularly in breast and lung cancers, these
markers are not routinely used in the clinic because of
their low sensitivity.(88) CYFRA 21-1 might have prog-
nostic relevance in HCC,(91,92) but further studies are
needed to clarify its usefulness. Given the emerging
negative prognostic value of K19 expression in
HCC,(93) future studies should assess the ratio between
serum K19 (CYFRA 21-1) and K18 levels (M65/
TPS). Finally, CYFRA 21-1 and/or serum K19/K18
ratio may be helpful to discriminate between HCC and
intrahepatic cholangiocarcinoma given that the latter
displays stronger K19 expression.(94)
Numerous reports have assessed the potential useful-
ness of the above-mentioned tumor markers in liver dis-
ease. For CYFRA 21-1, the diagnostic benefit in
nonmalignant liver diseases is likely small given that K19
is expressed only in cholangiocytes in unstressed livers,
and even upon injury, hepatocellular K19 levels are
rather low.(9) Although CYFRA 21-1 has not been
adequately assessed in cholestatic liver disorders, it has
been studied in the context of other liver diseases. For
example, patients with alcoholic hepatitis displayed
increased CYFRA 21-1 levels,(95) which meshes well
with the associated strong ductular reaction.(96) Unlike
CYFRA 21-1, TPA and TPS are commonly elevated in
patients with both malignant and nonmalignant liver
diseases and therefore lack sufficient specificity for HCC
detection.(97) On the other hand, increased TPS levels
may predict early HCC recurrence after curative resec-
tion.(97) In cirrhosis, TPA strongly correlates with (but
might be more sensitive than) AST values.(98) Moreover,
TPA might discriminate between subjects without and
with cirrhosis given that it correlates with hepatic vein
pressure gradient, a central parameter of portal hyperten-
sion.(99) TPS was found to be elevated in patients with
multiple nonmalignant liver diseases and to correlate
with AST levels and histological score of disease sever-
ity.(100) Of note, TPS was elevated in one third of liver
disease patients with normal liver enzyme values, sug-
gesting that it might be more sensitive than AST.(100) In
alcoholic liver disease subjects, TPS was lower in those
with less-severe steatosis/fibrosteatosis compared to
those with life-threatening alcoholic hepatitis.(101) TPS
levels also correlated with the extent of Mallory-Denk
bodies (K8/K18-containing inclusions characteristic of
alcoholic liver disease/NASH),(9) but the clinical signifi-
cance of this finding remains unknown.(101) In NAFLD,
one study found TPS to be superior to ALT in discrimi-
nating NASH from simple steatosis.(102) Despite these
interesting findings, more work is needed on TPA/TPS
to evaluate whether or not they offer an advantage to
already established parameters. Given their biological
similarity, it is tempting to speculate that TPS and M65
might be equally useful for subclassification of nonmalig-
nant liver disorders.
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FIG. 3. Number of published original articles using K18 bio-
markers (M30 or M65) in NAFLD (n 5 70), HBV (n 5 10),
HCV (n 5 17) infections, and other liver diseases (n 5 45).
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FIG. 4. K19 cleavage during apoptosis. Human K19 has one
caspase cleavage site at VEVD238 that is conserved among other
intermediate filaments. The CYFRA 21-1 assay (Cisbio Bioas-
says, Codolet, France) is performed using two monoclonal anti-
bodies for K19: The capture antibody Ks 19.1 (recognizes 311-
335aa) and the detection antibody BM 19.21 (recognizes 346-
367aa). The CYFRA 21-1 assay does not discriminate between
apoptotic and total cell death because both antibodies simply rec-
ognize the K19 rod domain. Abbreviation: aa, amino acids.
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For liver injury, the M30 ELISA is a biologically
sound reflection of the extent of early-stage hepatocyte/
cholangiocyte apoptosis, though necrosis may accom-
pany apoptosis. Moreover, intact keratins or non-cas-
pase generated keratin fragments may be released
during apoptosis. Notably, M30 does not measure late
apoptosis stages that include generation of the second
K18 caspase cleavage product, and, at least in cell cul-
ture systems, the M30 reactivity disappears in some
apoptotic cells whereas reactivity of the antibody that
recognizes the K18 second cut site persists.(33) Also, an
important unknown is the stability of various keratin
species in serum in the context of different liver diseases.
This caveat applies to all the currently used ELISAs
that detect M30/M65/TPA/TPS/CYFRA 21-1.
With regard to the M65 ELISA, it is used to mea-
sure serum/plasma total or fragment K18 species using
the monoclonal antibodies, M5 and M6, whose epi-
topes are located between K18 amino acids 300-
380(90) (Fig. 1). Hence, M65 detects not only nona-
poptotic K18 fragments and intact K18, but also the
159aa apoptotic K18 fragment. This indicates that the
M65 ELISA does not exclusively represent nonapop-
totic K18, and that M65 may overlap with TPA and
TPS depending on the biological and clinical contexts.
Another variable that is usually not accounted for in
studies that measured keratin fragments is the presence
of nonhepatic epithelial tissue injury or inflammation
(gastrointestinal, lung, and kidney; tissues that express
K8/K18/K19). Such extrahepatobiliary organ involve-
ment could provide false-positive readings of K8/K18/
K19 fragments, given that these keratins and their
fragments can also spill into the circulation.
Although numerous studies have measured keratin
fragments as biomarkers of liver (Fig. 3 and Support-
ing Table 1) and other tissue injury, it is important to
have a better appreciation of the species that are being
measured. For example, it would be meaningful to
compare the M30/M65 assays with (currently unavail-
able) ELISAs that would detect epitopes spanning the
undigested K18 aspartates, 238 and 397. Also, there is
no available ELISA that is directed to K18 Asp238,
and such an ELISA, once established, is predicted to
recognize both K18/K19 aspartates given their
conserved proximal sequence. Mass spectrometry and
other immunobiochemical tools may also help define
the precise nature of the keratin species in sera from
patients with different liver and other diseases that
associate with release of K8/K18/K19 species. For
example, it is possible that PTMs of circulating intact
keratins or their fragments may provide an added
dimension to use as biomarkers.(26)
In conclusion, the detection of circulating keratin
species remains a useful adjunct for the assessment of
liver injury. The abundance of keratins in liver tissue
and normal physiologic presence in the cytoplasm,
coupled with their relative stability,(9,33) provide
important support for their use as durable and sensitive
liver injury biomarkers. Furthermore, the nature of
keratin fragments (apoptotic vs. nonapoptotic) might
provide insight regarding the cause(s) of liver injury.
Better understanding of the mode of release and
biochemical form of circulating keratins will likely
enhance their diagnostic and potential prognostic
utility.
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